Current Headlines

  1. ICR Completes New Deal With Company To Develop Ovarian Cancer Drug

    The Institute of Cancer Research, London and global healthcare company BTG have successfully concluded negotiations with a biopharmaceutical company, Carrick Therapeutics, to take a promising precision drug discovered at The Institute of Cancer Research into a later-stage clinical trial.

  2. InSphero Achieves New Milestone With Akura™ Flow Organ-On-A-Chip Technology In Low-Clearance Drug Study

    InSphero AG today announced that it has successfully completed a collaborative project with the FHNW University in Switzerland to develop a 3D organ-on-a-chip assay for predicting metabolic stability of low clearance compounds in pharmaceutical drug development.

  3. OSE Immunotherapeutics And Oncology Physician Network GERCOR Announce Submission Of Investigational New Drug Application To Evaluate Tedopi® In Combination With Nivolumab In Pancreatic Cancer

    OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announced the submission of an Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of Tedopi® in advanced or metastatic pancreatic cancer.

  4. New Options For Breast Cancer Drug Development Found In Estrogen Receptors

    Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually develop drug resistance, leaving doctors desperate for alternatives.

  5. Neurocrine Biosciences And Jnana Therapeutics Enter Strategic Collaboration To Discover Novel Medicines To Treat Central Nervous System Disorders

    Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Jnana Therapeutics Inc. today announced that they have entered into a research collaboration aimed at discovering novel small molecule therapeutics for multiple targets for central nervous system (CNS) disorders

  6. BioDuro Launches New Drug Discovery Site In San Diego, CA

    BioDuro LLC, a leading global life sciences contract research and development organization announced today that it has established a new drug discovery center for chemistry and biology in San Diego, CA

  7. Assessing Health Impact Of New Antimicrobials Could Encourage Further Drug Development

    In a new report, researchers at the University of York have investigated the ways in which the value of new antimicrobial drugs could be assessed to help the NHS decide how much should be paid for them

  8. Breakthrough Drug Shows Early Promise For Multiple Myeloma

    Multiple myeloma is a relatively rare type of cancer that develops in the bone marrow – the spongey tissue inside the bone where new blood cells are produced – often spreading to multiple sites within the body

  9. Evotec Signs Agreement With Sanofi To Advance Early Stage Academic Research Into Novel Therapeutic Candidates

    Evotec AG announced recently that it has established an initiative with Sanofi through the launch of a newly created BRIDGE, called LAB031, designed to accelerate drug discovery across multiple therapeutic areas

  10. Cellectar Announces Overall Survival Exceeding 19 Months In Phase 1b Trial With CLR 131 In Relapsed/Refractory Multiple Myeloma

    Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today updates interim overall survival (OS) data from the company’s ongoing Phase 1b clinical trial evaluating CLR 131 for the treatment of relapsed/refractory (R/R) multiple myeloma (MM).